primobolan depot

Stimulates the body’s α, β and γ-interferons. Major producers of interferon in response to primobolan depot are intestinal epithelial cells, hepatocytes, T-lymphocytes, and neutrophils. After oral administration, maximum production of interferon is defined in the sequence gut-liver-blood through the 4-24 hours,primobolan depot has immunomodulatory and antiviral effect. It stimulates bone marrow stem cells, in a dose dependent increases antibody reduces the degree of immunosuppression, restores ratio of T-helpers / T-suppressors. It is effective against a variety of viral infections, including influenza virus, and other acute respiratory viral infections, hepatitis viruses and herpes viruses. The mechanism of antiviral action due to inhibition of translation of virus-specific proteins in the infected cells, whereby virus replication is inhibited.

Indications

In adults, for the treatment of viral hepatitis A, B, C, herpes infection, cytomegalovirus infection, in the complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leykoentsefality, uveoentsefality et al.), In the primobolan depot complex therapy of urogenital and respiratory chlamydia, for treatment and prevention of influenza and other acute respiratory viral infections.

Contraindications

Hypersensitivity to the drug. Pregnancy and lactation.
Children’s age (up to 7 years).

Dosing and Administration

The drug is taken orally after a meal. For a non-specific prevention of hepatitis A -. 0.125 g per week for 6 weeks for the treatment of viral hepatitis A – the first day to 0,125 g, 2 times, and then to 0,125 gcherez 48 hours. The course of treatment of 1.25 g (10 tablets). For the treatment of acute hepatitis B – the first and second days of 0,125 g, followed by 0.125 g in 48 hours. The treatment of 2 g (16 tablets), with a protracted course of hepatitis B – 0.125 g of 2 times a day on the first day, followed by 0.125 g in 48 hours. The treatment of 2.5 g (20 tablets). In chronic hepatitis B – initial phase of treatment (2.5 g – 20 tablets) – the first two days of 0.25 g, then 0.125 g in 48 hours. Continuation phase (1.25 g – 10 2.5 g tablets 20 tablets) – 0,125 g per week. Heading dose Lavomaksa® from 3.75 g to 5 g, duration of treatment 3,5-6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process. In acute hepatitis C – the first and second days of 0,125 g, then to 0,125 g in 48 hours. The treatment of 2.5 g (20 tablets). In chronic hepatitis C – initial phase of treatment (2.5 g – 20 tablets) – the first two days of 0.25 g, then 0.125 g in 48 hours.Continuation phase (2.5 g, 20 tablets) – 0,125 g per week. Heading dose Lavomaksa® – 5 g, duration of treatment – 6 months depending on the results of biochemical, immunological, morphological markers of activity of the process. In the treatment of influenza and other acute respiratory viral infections – in the first two days of illness to 0,125 g, then after 48 hours at 0,125 g in the course of treatment primobolan depot of 0.750 for the prevention of influenza and other acute respiratory viral infections – 0,125 g once a week for 6 weeks. For treatment of herpes, cytomegalovirus infection – the first two days of 0,125 g, then after 48 hours at 0,125 g heading dose of 2, 5 of urogenital and respiratory chlamydia – the first two days of 0,125 g, then after 48 hours at 0,125 g heading dose of 1.25 g When the complex treatment of infections neyrovirusnyh dose set individually, a course of treatment is 4 weeks.